secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-09-19T23:59:59+00:00
Accession:  0001564590-22-031834
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi reports positive Phase 2 CANAL data: Haduvio reduces daytime cough 75% vs 23% placebo
--------------------------------------------------------------------------------

- Primary endpoint met: placebo-adjusted daytime cough frequency reduction 52.5% (p<0.0001).
- Haduvio achieved 76.1% reduction in 24-hour cough frequency vs 25.3% placebo (p<0.0001).
- 97% of Haduvio subjects had ≥30% reduction in 24-hour cough vs 35% placebo (p<0.0001).
- Company aims to initiate Phase 2b in chronic cough IPF in H1 2023, Phase 3 in prurigo nodularis in H1 2023.
- Safety consistent with prior trials; most common adverse events: nausea, fatigue, constipation, dizziness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022031834/0001564590-22-031834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022031834/trvi-8k_20220919.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-031834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer